Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Aion Therapeutic Inc C.AION

Alternate Symbol(s):  ANTCF

Aion Therapeutic Inc is in the business of research and development, treatment, data mining and state-of-the-art artificial intelligence techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations, and other medicinal plants in a legal environment for... see more

CSE:AION - Post Discussion

Aion Therapeutic Inc > Biden Signs Defense Spend Bill Funding Psychedelic Research
View:
Post by RisePrize007 on Dec 29, 2023 12:07pm

Biden Signs Defense Spend Bill Funding Psychedelic Research

President Joseph Biden last week signed a defense spending bill that funds clinical trials researching psychedelic drugs to treat post-traumatic stress disorder and traumatic brain injuries experienced by active-duty members of the U.S. military. The president signed the legislation, known as the National Defense Authorization Act (NDAA), on Friday after the bill was approved by Congress earlier this month.

 

Under the legislation, the Department of Defense would be required to establish a system to allow active-duty service members with post-traumatic stress disorder (PTSD) or traumatic brain injuries (TBI) to participate in clinical trials studying the psychedelic drugs psilocybin, MDMA, ibogaine and 5-MeO-DMT as treatments for their conditions. The legislation appropriates $10 million for psychedelics research, which could be conducted in conjunction with academic institutions and eligible federal and state agencies. The measure also sets a 180-day time limit from the day the bill becomes effective for the Department of Defense to establish the psychedelics research program.https://www.forbes.com/sites/ajherrington/2023/12/27/biden-signs-defense-spending-bill-funding-psychedelic-research/amp/

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities